-
Hengrui Medicine’s Pyrotinib Combo Meets Endpoints in HER2+ Breast Cancer Trial
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its tyrosine kinase inhibitor (TKI) pyrotinib, combined with trastuzumab and docetaxel, met endpoints in a Phase III clinical trial as a first-line treatment for HER2-positive recurrent/metastatic breast cancer. The company plans to hold pre-market approval filing discussions with regulators soon. Study…
-
Shouyao Holdings Receives Approval for CT-3505 ALK Inhibitor Study in NSCLC
•
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced it has received ethical approval from the Cancer Institute and Hospital at the Chinese Academy of Military Science to conduct a Phase I/II clinical study (CT-3505-I-01) of its CT-3505 in patients with ALK-positive non-small cell lung cancer (NSCLC). Drug ProfileCT-3505, an…
-
InnoCare Pharma Doses First Patient in ICP-488 Study for Autoimmune Diseases
•
China-based InnoCare Pharma (HKG: 9969) announced that the first subject has been dosed in a clinical study for ICP-488, its TYK2 JH2 allosteric inhibitor. The drug is being developed for autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD). Mechanism of ActionICP-488 is a potent and selective inhibitor of…
-
Convalife Pharmaceuticals Licenses Karus Therapeutics’ CVL237 Globally
•
Shanghai-based Convalife Pharmaceuticals has entered into a licensing agreement with UK-based Karus Therapeutics Ltd, acquiring global patents, development, and commercialization rights to CVL237 (KA2237). Financial terms were not disclosed. Drug ProfileCVL237 is a dual selective inhibitor of phosphatidylinositol-3-kinase (PI3K) β/δ. It is advancing into Phase II trials in China and…
-
Unicycive Therapeutics Licenses Renazorb to Lee’s Pharma for Asian Markets
•
U.S.-based biotech Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced a licensing agreement with Hong Kong-listed Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), granting Lee’s exclusive rights to develop, market, and commercialize Renazorb (lanthanum dioxycarbonate) in mainland China, Hong Kong, and other Asian markets. Licensing TermsUnder the agreement, Unicycive will receive an upfront…
-
HutchMed Initiates China Bridging Study for Tazverik in Follicular Lymphoma
•
HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a bridging study for Tazverik (tazemetostat) in China, with the first patient dosed on July 29, 2022. The multi-center, open-label, Phase II study (NCT05467943) will evaluate the drug’s efficacy, safety, and pharmacokinetics in relapsed/refractory follicular lymphoma (FL). Drug BackgroundTazverik, an EZH2…
-
Hainan Shuangcheng to Transfer Triptorelin Assets to Chongqing Lummy for USD 4.7M
•
Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) will transfer all tangible and intangible assets and rights related to its triptorelin product in designated territories to Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) for RMB 32 million (USD 4.7 million). The deal includes intellectual property, production technology, and marketing approvals for…
-
Eccogene Receives FDA Approval for ECC4703 Phase I Study in NASH and Dyslipidemia
•
Shanghai-based biopharmaceutical company Eccogene announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial for ECC4703, a thyroid hormone receptor (THR) agonist. The study will assess the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants and subjects with elevated…
-
HutchMed’s H1 2022 Oncology Sales Surge 82% on Strong Product Performance
•
China-based biopharma HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) reported strong financial results for the first half of 2022, with oncology product sales soaring 82% year-on-year (YOY) to USD 87.4 million. The company expanded its commercial team to 800 staff, driving growth across its key products. Product Sales Breakdown Revenue…
-
Lion TCR Enrolls First Patient in LioCyx-M004 Study for HBV-Related Liver Cancer
•
Singapore-based clinical-stage biotech Lion TCR announced the enrollment of the first subject in a clinical study for LioCyx-M004, its autologous T-cell therapy targeting HBV-related hepatocellular carcinoma (HCC). The therapy uses mRNA-engineered T-cells to recognize and destroy hepatitis B virus (HBV)-related liver cancer cells. Therapy DetailsLioCyx-M004 leverages Lion TCR’s RNA technology…
-
Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review
•
Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has accepted Investigational New Drug (IND) filings for TLX591-CDx (Illuccix) and TLX250-CDx, its radiopharmaceuticals for prostate cancer and clear cell renal cell carcinoma (ccRCC) diagnostics. Drug Profiles China Trials Global DevelopmentTLX591-CDx is filed for marketing in…
-
OriginCell Therapeutics Raises USD 120M in Series B for Tumor Immunotherapy Pipeline
•
OriginCell Therapeutics, a Shanghai-based tumor immunotherapy specialist, reportedly raised over USD 120 million in a Series B financing round. The round was co-led by Qiming Venture Partners and Quan Capital, with participation from Shanghai Science and Technology Innovation Center Equity Investment Fund, Sinopharm Capital, Suzhou Fund, Boquan Equity Investment Management,…
-
Fosun Pharma to Hike Aitrox Stake to 72.63% for USD 61M
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) plans to increase its ownership of Aitrox from 28.23% to 72.63% in a deal valued at RMB 412.35 million (USD 61 million). The investment includes a direct capital injection of RMB 50 million (USD 7.4 million) and the acquisition of…
-
GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline
•
GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly raised USD 22 million in a Series A+ financing round. The round brings the company’s total funding to USD 90 million since its founding in March 2023. Existing investor Qiming Venture Partners led the round,…
-
BridGene Biosciences Completes USD 38.5M Series B Round with China Funds
•
U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5 million. The round was backed by China-based funds, including Beijing’s Lapam Capital, Hong Kong’s Junson Capital, and Xiamen’s Dyee Capital. Funding UseProceeds will support the development of BridGene’s proprietary chemoproteomic platform IMTAC, including clinical trials…
-
Basecare Medical Sells 35% Stake in Cellpro Biotech for USD 9.5M
•
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based IVF specialist, will sell a 35% stake in its assisted reproductive product developer Zhejiang Cellpro Biotech Co., Ltd for RMB 64.17 million (USD 9.5 million). Post-deal, Basecare will retain a 15% stake in Cellpro, having previously acquired 51% of the firm…
-
Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial
•
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical (Shanghai) Co., Ltd, has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical study of BC007, a bispecific antibody (BsAb) targeting CLDN18.2 and CD47, in patients with solid…
-
Pica Partners with BrainCo to Launch ADHD Product in China
•
Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with BrainCo, a firm operating in China and the U.S., to launch the latter’s ADHD product in China. Financial details of the deal were not disclosed. Product DetailsThe ADHD product features a smart, non-invasive brain-computer interface…
-
NHC Designates National Mental Illness Medical Centers in Beijing and Shanghai
•
The National Healthcare Commission (NHC) announced the establishment of national mental illness medical centers, designating Peking University Sixth Hospital and Beijing Anding Hospital of Capital Medical University as joint main bodies. Shanghai Mental Health Center and the Second Xiangya Hospital of Central South University will also establish separate national mental…
